Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
- PMID: 20594588
- PMCID: PMC4123233
- DOI: 10.1016/S0140-6736(10)60576-4
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
Erratum in
- Lancet. 2010 Oct 30;376(9751):1466
Abstract
Background: Hyperglycaemia is associated with increased risk of cardiovascular complications in people with type 2 diabetes. We investigated whether reduction of blood glucose concentration decreases the rate of microvascular complications in people with type 2 diabetes.
Methods: ACCORD was a parallel-group, randomised trial done in 77 clinical sites in North America. People with diabetes, high HbA(1c) concentrations (>7.5%), and cardiovascular disease (or >or=2 cardiovascular risk factors) were randomly assigned by central randomisation to intensive (target haemoglobin A(1c) [HbA(1c)] of <6.0%) or standard (7.0-7.9%) glycaemic therapy. In this analysis, the prespecified composite outcomes were: dialysis or renal transplantation, high serum creatinine (>291.7 micromol/L), or retinal photocoagulation or vitrectomy (first composite outcome); or peripheral neuropathy plus the first composite outcome (second composite outcome). 13 prespecified secondary measures of kidney, eye, and peripheral nerve function were also assessed. Investigators and participants were aware of treatment group assignment. Analysis was done for all patients who were assessed for microvascular outcomes, on the basis of treatment assignment, irrespective of treatments received or compliance to therapies. ACCORD is registered with ClinicalTrials.gov, number NCT00000620.
Findings: 10 251 patients were randomly assigned, 5128 to the intensive glycaemia control group and 5123 to standard group. Intensive therapy was stopped before study end because of higher mortality in that group, and patients were transitioned to standard therapy. At transition, the first composite outcome was recorded in 443 of 5107 patients in the intensive group versus 444 of 5108 in the standard group (HR 1.00, 95% CI 0.88-1.14; p=1.00), and the second composite outcome was noted in 1591 of 5107 versus 1659 of 5108 (0.96, 0.89-1.02; p=0.19). Results were similar at study end (first composite outcome 556 of 5119 vs 586 of 5115 [HR 0.95, 95% CI 0.85-1.07, p=0.42]; and second 1956 of 5119 vs 2046 of 5115, respectively [0.95, 0.89-1.01, p=0.12]). Intensive therapy did not reduce the risk of advanced measures of microvascular outcomes, but delayed the onset of albuminuria and some measures of eye complications and neuropathy. Seven secondary measures at study end favoured intensive therapy (p<0.05).
Interpretation: Microvascular benefits of intensive therapy should be weighed against the increase in total and cardiovascular disease-related mortality, increased weight gain, and high risk for severe hypoglycaemia.
Funding: US National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute on Aging; National Eye Institute; Centers for Disease Control and Prevention; and General Clinical Research Centers.
Copyright 2010 Elsevier Ltd. All rights reserved.
Figures
![Figure A1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f1.gif)
![Figure A2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f2.gif)
![Figure A3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f3.gif)
![Figure A4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f4.gif)
![Figure A5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f5.gif)
![Figure A6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f6.gif)
![Figure A7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f7.gif)
![Figure A8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f8.gif)
![Figure A9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f9.gif)
![Figure A10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f10.gif)
![Figure A11](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f11.gif)
![Figure A12](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f12.gif)
![Figure A13](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f13.gif)
![Figure A14](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f14.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f15.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f16.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f17.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f18.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f19.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4123233/bin/nihms228817f20.gif)
Comment in
-
Intensive treatment of hyperglycaemia: ACCORD.Lancet. 2010 Aug 7;376(9739):391-2. doi: 10.1016/S0140-6736(10)61028-8. Epub 2010 Jun 30. Lancet. 2010. PMID: 20594590 No abstract available.
-
Mixed messages on systemic therapies for diabetic retinopathy.Lancet. 2010 Oct 30;376(9751):1461; author reply 1462. doi: 10.1016/S0140-6736(10)61985-X. Lancet. 2010. PMID: 21036264 No abstract available.
-
Mixed messages on systemic therapies for diabetic retinopathy.Lancet. 2010 Oct 30;376(9751):1461; author reply 1462. doi: 10.1016/S0140-6736(10)61984-8. Lancet. 2010. PMID: 21036265 No abstract available.
-
Reduktion mikrovaskulärer Komplikationen bei intensiver Behandlung des Diabetes. Der Preis ist ein Anstieg der Mortalität.Praxis (Bern 1994). 2010 Nov 3;99(22):1372-3. doi: 10.1024/1661-8157/a000297. Praxis (Bern 1994). 2010. PMID: 21049446 German. No abstract available.
-
ACP Journal Club. Intensive glucose control did not reduce a composite of microvascular events more than standard control in type 2 diabetes.Ann Intern Med. 2010 Nov 16;153(10):JC5-9. doi: 10.7326/0003-4819-153-10-201011160-02009. Ann Intern Med. 2010. PMID: 21079216 No abstract available.
Similar articles
-
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.Cochrane Database Syst Rev. 2014 Feb 14;2014(2):CD009122. doi: 10.1002/14651858.CD009122.pub2. Cochrane Database Syst Rev. 2014. PMID: 24526393 Free PMC article. Review.
-
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.Cochrane Database Syst Rev. 2013 Nov 11;(11):CD008143. doi: 10.1002/14651858.CD008143.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2015 Jul 29;(7):CD008143. doi: 10.1002/14651858.CD008143.pub4. PMID: 24214280 Updated. Review.
-
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.Lancet Neurol. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0. Epub 2011 Sep 28. Lancet Neurol. 2011. PMID: 21958949 Free PMC article. Clinical Trial.
-
The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.BMJ. 2010 Jan 8;340:b5444. doi: 10.1136/bmj.b5444. BMJ. 2010. PMID: 20061360 Free PMC article. Clinical Trial.
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet. 1998 Sep 12;352(9131):837-53. Lancet. 1998. PMID: 9742976 Clinical Trial.
Cited by
-
Diabetic peripheral neuropathy: age-stratified glycemic control.Front Endocrinol (Lausanne). 2024 Apr 17;15:1377923. doi: 10.3389/fendo.2024.1377923. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38694945 Free PMC article.
-
Diabetic Kidney Disease Prevention Care Model Development.Clin Diabetes. 2024 Spring;42(2):274-294. doi: 10.2337/cd23-0063. Epub 2023 Dec 6. Clin Diabetes. 2024. PMID: 38694240
-
Personalised prediction of maintenance dialysis initiation in patients with chronic kidney disease stages 3-5: a multicentre study using the machine learning approach.BMJ Health Care Inform. 2024 Apr 27;31(1):e100893. doi: 10.1136/bmjhci-2023-100893. BMJ Health Care Inform. 2024. PMID: 38677774 Free PMC article.
-
Novel drugs affecting diabetic peripheral neuropathy.Iran J Basic Med Sci. 2024;27(6):657-670. doi: 10.22038/IJBMS.2024.75367.16334. Iran J Basic Med Sci. 2024. PMID: 38645500 Free PMC article. Review.
-
A Systematic Guideline by the ASPN Workgroup on the Evidence, Education, and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET.J Pain Res. 2024 Apr 13;17:1461-1501. doi: 10.2147/JPR.S451006. eCollection 2024. J Pain Res. 2024. PMID: 38633823 Free PMC article. Review.
References
-
- Klein R, Klein EK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 1984;102:527–32. - PubMed
-
- Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS50: Risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156–63. - PubMed
-
- Ballard DJ, Humphrey LL, Melton LJ, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes. 1988;37:405–12. - PubMed
-
- UK Prospective Diabetes Study Group. X. Urinary albumin excretion over 3 years in diet-treated Type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia. 1993;36:1021–9. - PubMed
-
- Adler AI, Boyko EJ, Ahroni JH, et al. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care. 1997;20:1162–7. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- N01HC95183/HC/NHLBI NIH HHS/United States
- Y01 HC001010/HC/NHLBI NIH HHS/United States
- N01HC95178/HC/NHLBI NIH HHS/United States
- N01-HC-95180/HC/NHLBI NIH HHS/United States
- IAA-Y1-HC-1010/HC/NHLBI NIH HHS/United States
- N01-HC-95183/HC/NHLBI NIH HHS/United States
- N01-HC-95178/HC/NHLBI NIH HHS/United States
- N01HC95182/HC/NHLBI NIH HHS/United States
- N01-HC-95179/HC/NHLBI NIH HHS/United States
- N01-HC-95181/HC/NHLBI NIH HHS/United States
- N01-HC-95184/HC/NHLBI NIH HHS/United States
- R01 HL073030/HL/NHLBI NIH HHS/United States
- N01HC95180/HC/NHLBI NIH HHS/United States
- N01HC95181/HC/NHLBI NIH HHS/United States
- N01HC95184/HC/NHLBI NIH HHS/United States
- N01-HC-95182/HC/NHLBI NIH HHS/United States
- IAA-Y1-HC-9035/HC/NHLBI NIH HHS/United States
- N01HC95179/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous